FRA
GILD icon

Frank Rimerman Advisors’s Gilead Sciences GILD Stock Holding History

Frank Rimerman Advisors’s Portfolio GILD Stock Details GILD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.46M Buy
35,286
+181
+0.5% +$23.8K 0.25% 61
2026
Q1 		$4.89M Hold
35,105
– – 0.32% 52
2025
Q4 		$4.31M Buy
35,105
+84
+0.2% +$10.2K 0.27% 56
2025
Q3 		$3.89M Buy
35,021
+2,942
+9% +$334K 0.25% 63
2025
Q2 		$3.56M Sell
32,079
-685
-2% -$72.9K 0.24% 66
2025
Q1 		$3.67M Buy
32,764
+446
+1% +$46K 0.29% 53
2024
Q4 		$2.99M Buy
32,318
+232
+0.7% +$20.9K 0.22% 72
2024
Q3 		$2.69M Buy
32,086
+2,252
+8% +$172K 0.19% 90
2024
Q2 		$2.05M Buy
29,834
+29,185
+4,497% +$1.95M 0.14% 116
2024
Q1 		$47.5K Buy
649
+208
+47% +$16K 0.01% 129
2023
Q4 		$35.7K Buy
+441
New +$34.3K 0.01% 130

Other funds holding GILD

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Frank Rimerman Advisors's GILD Position: Q2 2026 in Review

Frank Rimerman Advisors increased its Gilead Sciences (GILD) stake by 0.52% in Q2 2026, buying an estimated $23.8K and bringing the position to 35,286 shares worth $4.46M. The position accounts for 0.25% of the portfolio, ranked #61.

Frank Rimerman Advisors first reported a position in GILD in Q4 2023 and has held it in 11 quarters since. The position peaked at $4.89M in Q1 2026. 2,285 funds tracked by Wall St. Rank hold GILD as of Q2 2026.

  • Frank Rimerman Advisors held 35,286 shares of Gilead Sciences worth $4.46M as of Q2 2026.
  • Frank Rimerman Advisors bought 181 Gilead Sciences shares in Q2 2026, an estimated $23.8K.
  • Gilead Sciences made up 0.25% of Frank Rimerman Advisors's portfolio in Q2 2026, its #61 holding.
  • Frank Rimerman Advisors first reported a position in Gilead Sciences in Q4 2023 and has held it in 11 quarters since.
  • Frank Rimerman Advisors's Gilead Sciences position peaked at $4.89M in Q1 2026.
  • 2,285 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2026.

Based on Frank Rimerman Advisors's 13F filing for Q2 2026, filed 27 Jul 2026.